Sarah Cannon Research Institute
@scri.com
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development.
MorningSun trial shows SC mosunetuzumab is effective & well-tolerated for elderly or CIT-ineligible #DLBCL patients. Featuring SCRI’s Dr. Jeff Sharman:
www.hmpgloballearningnetwork.com/site/onc/new... #ASH25 #InnovationInOncology #SCRI
www.hmpgloballearningnetwork.com/site/onc/new... #ASH25 #InnovationInOncology #SCRI
Client Challenge
Please enable JavaScript to proceed.
www.hmpgloballearningnetwork.com
December 15, 2025 at 10:01 PM
MorningSun trial shows SC mosunetuzumab is effective & well-tolerated for elderly or CIT-ineligible #DLBCL patients. Featuring SCRI’s Dr. Jeff Sharman:
www.hmpgloballearningnetwork.com/site/onc/new... #ASH25 #InnovationInOncology #SCRI
www.hmpgloballearningnetwork.com/site/onc/new... #ASH25 #InnovationInOncology #SCRI
Congrats to our SCRI team for powering 100 abstracts & 50+ investigator-led presentations across hematologic diseases.
Patients remain at the center of all we do—here’s to driving impact beyond Orlando!
#SCRI
Patients remain at the center of all we do—here’s to driving impact beyond Orlando!
#SCRI
December 11, 2025 at 7:46 PM
Congrats to our SCRI team for powering 100 abstracts & 50+ investigator-led presentations across hematologic diseases.
Patients remain at the center of all we do—here’s to driving impact beyond Orlando!
#SCRI
Patients remain at the center of all we do—here’s to driving impact beyond Orlando!
#SCRI
We’re proud to share Dr. Erika Hamilton's latest publication in Journal of Clinical Oncology: #HER2CLIMB05, a Phase 3 study evaluating tucatinib in combo w/trastuzumab + pertuzumab as first-line maintenance therapy for HER2+ #metastaticbreastcancer.
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer
PurposeThe HER2CLIMB-05 study (ClinicalTrials.gov identifier: NCT05132582) is investigating the efficacy and safety of adding tucatinib to trastuzumab and
pertuzumab as first-line (1L) maintenance the...
ascopubs.org
December 10, 2025 at 10:45 PM
We’re proud to share Dr. Erika Hamilton's latest publication in Journal of Clinical Oncology: #HER2CLIMB05, a Phase 3 study evaluating tucatinib in combo w/trastuzumab + pertuzumab as first-line maintenance therapy for HER2+ #metastaticbreastcancer.
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
Didn’t have a chance to meet our experts at #ASH25 booth 1580? Learn from them during their presentations today!
View the schedule: scriash2025.com
View the schedule: scriash2025.com
December 8, 2025 at 4:03 PM
Didn’t have a chance to meet our experts at #ASH25 booth 1580? Learn from them during their presentations today!
View the schedule: scriash2025.com
View the schedule: scriash2025.com
Meet #SCRI experts at #ASH25. Visit booth 1580 and view our full schedule: uberflip.scri.com/i/1541695-me...?
December 7, 2025 at 3:23 PM
Meet #SCRI experts at #ASH25. Visit booth 1580 and view our full schedule: uberflip.scri.com/i/1541695-me...?
Dr. Burke takes the #ASH25 stage to answer the question: How Can Community-Based and Academic Hematologists Foster Clinical Trial Participation as Part of Patient Care?
December 7, 2025 at 2:55 PM
Dr. Burke takes the #ASH25 stage to answer the question: How Can Community-Based and Academic Hematologists Foster Clinical Trial Participation as Part of Patient Care?
SCRI expert, Dr. Hans Lee serves as session chair during “#MultipleMyeloma: Pharmacologic Therapies: Advances in Treatment Strategies for Relapsed/Refractory Multiple Myeloma.” #ASH25
December 6, 2025 at 8:05 PM
SCRI expert, Dr. Hans Lee serves as session chair during “#MultipleMyeloma: Pharmacologic Therapies: Advances in Treatment Strategies for Relapsed/Refractory Multiple Myeloma.” #ASH25
From AGAVE‑201, Dr. Farhadfar reports that switching to axatilimab 0.6 mg/kg Q4W was safe, feasible, and showed no new signals vs 0.3 mg/kg Q2W. Patients remained on therapy long‑term (median 1.7 y), with 84% continuing—suggesting ongoing benefit. #ASH25
December 6, 2025 at 8:03 PM
From AGAVE‑201, Dr. Farhadfar reports that switching to axatilimab 0.6 mg/kg Q4W was safe, feasible, and showed no new signals vs 0.3 mg/kg Q2W. Patients remained on therapy long‑term (median 1.7 y), with 84% continuing—suggesting ongoing benefit. #ASH25
Hematology is evolving fast, and SCRI experts are leading the way. Ahead of #ASH25, explore 5 trends shaping research and collaboration this year.
Read more: www.scri.com/news/sarah-c...
#SCRI #ASH25 #Hematology #Oncology
Read more: www.scri.com/news/sarah-c...
#SCRI #ASH25 #Hematology #Oncology
December 4, 2025 at 6:49 PM
Hematology is evolving fast, and SCRI experts are leading the way. Ahead of #ASH25, explore 5 trends shaping research and collaboration this year.
Read more: www.scri.com/news/sarah-c...
#SCRI #ASH25 #Hematology #Oncology
Read more: www.scri.com/news/sarah-c...
#SCRI #ASH25 #Hematology #Oncology
Sarah Cannon Research Institute will present 100 abstracts at #ASH25, marking our largest presence yet. 50+ investigators will share breakthroughs in blood cancers & disorders. Learn more: www.scri.com/news/sarah-c...
December 2, 2025 at 7:43 PM
Sarah Cannon Research Institute will present 100 abstracts at #ASH25, marking our largest presence yet. 50+ investigators will share breakthroughs in blood cancers & disorders. Learn more: www.scri.com/news/sarah-c...
Mike’s cancer journey shows the power of research + compassionate care. At SCRI, he found hope through clinical trials and unwavering support.
Watch his story: www.youtube.com/watch?v=29KR...
#CancerCare #ClinicalTrials #PatientStories
Watch his story: www.youtube.com/watch?v=29KR...
#CancerCare #ClinicalTrials #PatientStories
Mike: A Story of Hope & The Power of Clinical Trials
YouTube video by Sarah Cannon Research Institute
www.youtube.com
November 24, 2025 at 6:57 PM
Mike’s cancer journey shows the power of research + compassionate care. At SCRI, he found hope through clinical trials and unwavering support.
Watch his story: www.youtube.com/watch?v=29KR...
#CancerCare #ClinicalTrials #PatientStories
Watch his story: www.youtube.com/watch?v=29KR...
#CancerCare #ClinicalTrials #PatientStories
SCRI's Dr. Erika Hamilton shares updates in HER2+ breast cancer and explains how T-DXd is moving into curative settings, with DESTINY-Breast11 & 05 trials showing:
✅ 83% pCR rate
✅ Anthracycline-sparing
✅ Better disease-free survival
www.medpagetoday.com/meetingcover...
#ESMO25 #BreastCancer
✅ 83% pCR rate
✅ Anthracycline-sparing
✅ Better disease-free survival
www.medpagetoday.com/meetingcover...
#ESMO25 #BreastCancer
Meeting Coverage | MedPage Today
www.medpagetoday.com
November 18, 2025 at 8:02 PM
SCRI's Dr. Erika Hamilton shares updates in HER2+ breast cancer and explains how T-DXd is moving into curative settings, with DESTINY-Breast11 & 05 trials showing:
✅ 83% pCR rate
✅ Anthracycline-sparing
✅ Better disease-free survival
www.medpagetoday.com/meetingcover...
#ESMO25 #BreastCancer
✅ 83% pCR rate
✅ Anthracycline-sparing
✅ Better disease-free survival
www.medpagetoday.com/meetingcover...
#ESMO25 #BreastCancer
We’re expanding our collaboration with @bmsnews to accelerate cancer research and broaden access to clinical trials through SCRI’s Accelero model.
Read more: www.scri.com/news/sarah-c...
#CancerResearch #ClinicalTrials
Read more: www.scri.com/news/sarah-c...
#CancerResearch #ClinicalTrials
November 12, 2025 at 2:17 PM
We’re expanding our collaboration with @bmsnews to accelerate cancer research and broaden access to clinical trials through SCRI’s Accelero model.
Read more: www.scri.com/news/sarah-c...
#CancerResearch #ClinicalTrials
Read more: www.scri.com/news/sarah-c...
#CancerResearch #ClinicalTrials
November is #LungCancerAwarenessMonth.
#SCRI's Dr. Melissa Johnson joined NewsChannel 5 to discuss how early detection and clinical trials are transforming lung cancer care. From low-dose CT scans to bispecifics, the future of treatment is here.
www.newschannel5.com/news/let-me-...
#SCRI's Dr. Melissa Johnson joined NewsChannel 5 to discuss how early detection and clinical trials are transforming lung cancer care. From low-dose CT scans to bispecifics, the future of treatment is here.
www.newschannel5.com/news/let-me-...
November 7, 2025 at 5:59 PM
November is #LungCancerAwarenessMonth.
#SCRI's Dr. Melissa Johnson joined NewsChannel 5 to discuss how early detection and clinical trials are transforming lung cancer care. From low-dose CT scans to bispecifics, the future of treatment is here.
www.newschannel5.com/news/let-me-...
#SCRI's Dr. Melissa Johnson joined NewsChannel 5 to discuss how early detection and clinical trials are transforming lung cancer care. From low-dose CT scans to bispecifics, the future of treatment is here.
www.newschannel5.com/news/let-me-...
New data from HER2CLIMB-05: Tucatinib added to first-line maintenance therapy improves PFS in HER2+ metastatic breast cancer.
Dr. Erika Hamilton of SCRI shares insights on this promising approach.
Full Cancer Network story:
www.cancernetwork.com/view/tucatin...
#Oncology #BreastCancer #HER2CLIMB05
Dr. Erika Hamilton of SCRI shares insights on this promising approach.
Full Cancer Network story:
www.cancernetwork.com/view/tucatin...
#Oncology #BreastCancer #HER2CLIMB05
Tucatinib Regimen Improves PFS in HER2+ Metastatic Breast Cancer | CancerNetwork
The safety profile of tucatinib plus trastuzumab and pertuzumab was consistent with the established profiles of each individual agent.
www.cancernetwork.com
October 30, 2025 at 7:25 PM
New data from HER2CLIMB-05: Tucatinib added to first-line maintenance therapy improves PFS in HER2+ metastatic breast cancer.
Dr. Erika Hamilton of SCRI shares insights on this promising approach.
Full Cancer Network story:
www.cancernetwork.com/view/tucatin...
#Oncology #BreastCancer #HER2CLIMB05
Dr. Erika Hamilton of SCRI shares insights on this promising approach.
Full Cancer Network story:
www.cancernetwork.com/view/tucatin...
#Oncology #BreastCancer #HER2CLIMB05
Journalist Amy Robach opens up about discovering breast cancer after a filmed mammogram. SCRI’s Dr. Erika Hamilton shares expert tips on risk and prevention on the Drew Barrymore Show.
Watch here: www.thedrewbarrymoreshow.com/videos/journ...
#BreastCancerAwareness #SCRIExperts
Watch here: www.thedrewbarrymoreshow.com/videos/journ...
#BreastCancerAwareness #SCRIExperts
Journalist Who Discovered She Had Breast Cancer After Filming Mammogram Segment Shares Her Story
Journalist Who Discovered She Had Breast Cancer After Filming Mammogram Segment Shares Her Story
www.thedrewbarrymoreshow.com
October 28, 2025 at 7:51 PM
Journalist Amy Robach opens up about discovering breast cancer after a filmed mammogram. SCRI’s Dr. Erika Hamilton shares expert tips on risk and prevention on the Drew Barrymore Show.
Watch here: www.thedrewbarrymoreshow.com/videos/journ...
#BreastCancerAwareness #SCRIExperts
Watch here: www.thedrewbarrymoreshow.com/videos/journ...
#BreastCancerAwareness #SCRIExperts
SCRI expert Dr. Ben Garmezy shares insights on testicular cancer diagnosis, treatment choices, and patient education in this CURE Today feature.
Read more:
www.curetoday.com/view/stage-1...
#CancerEducation #TesticularCancer #SCRI
Read more:
www.curetoday.com/view/stage-1...
#CancerEducation #TesticularCancer #SCRI
Stage 1 Testicular Cancer: A Patient Education Overview | CURE
From diagnosis to treatment, here is what patients need to know about stage 1 testicular cancer.
www.curetoday.com
October 28, 2025 at 5:07 PM
SCRI expert Dr. Ben Garmezy shares insights on testicular cancer diagnosis, treatment choices, and patient education in this CURE Today feature.
Read more:
www.curetoday.com/view/stage-1...
#CancerEducation #TesticularCancer #SCRI
Read more:
www.curetoday.com/view/stage-1...
#CancerEducation #TesticularCancer #SCRI
PHAROS trial update: Half of treatment-naïve patients with BRAF V600E–mutant NSCLC treated with encorafenib + binimetinib are alive at 4 years.
Shoutout to Dr. Melissa Johnson for her leadership in advancing targeted therapy!
🔗 www.ajmc.com/view/long-te...
#CancerCare #Oncology #TargetedTherapy
Shoutout to Dr. Melissa Johnson for her leadership in advancing targeted therapy!
🔗 www.ajmc.com/view/long-te...
#CancerCare #Oncology #TargetedTherapy
Long-Term Data for PHAROS Show Half of Treatment-Naïve Patients Receiving Encorafenib Plus Binimetinib Alive at 4 Years | AJMC
A mini oral session at ESMO of targeted therapy in non-small cell lung cancer included treatments that showed effectiveness in brain metastases.
www.ajmc.com
October 23, 2025 at 5:51 PM
PHAROS trial update: Half of treatment-naïve patients with BRAF V600E–mutant NSCLC treated with encorafenib + binimetinib are alive at 4 years.
Shoutout to Dr. Melissa Johnson for her leadership in advancing targeted therapy!
🔗 www.ajmc.com/view/long-te...
#CancerCare #Oncology #TargetedTherapy
Shoutout to Dr. Melissa Johnson for her leadership in advancing targeted therapy!
🔗 www.ajmc.com/view/long-te...
#CancerCare #Oncology #TargetedTherapy
The future of oncology is here: AI-powered decisions, precision medicine, and collaborative care models. At #PCOC2025, experts—including Dr. Vivek Subbiah—explored how these innovations will improve patient outcomes.
🔗 www.ajmc.com/view/experts...
#HealthcareInnovation #Oncology #AI
🔗 www.ajmc.com/view/experts...
#HealthcareInnovation #Oncology #AI
Experts Highlight AI, Innovation, and Collaboration as Key PCOC Takeaways | AJMC
Five experts share their key takeaways from Patient-Centered Oncology Care® (PCOC) 2025, highlighting AI integration and collaboration to improve care.
www.ajmc.com
October 22, 2025 at 6:12 PM
The future of oncology is here: AI-powered decisions, precision medicine, and collaborative care models. At #PCOC2025, experts—including Dr. Vivek Subbiah—explored how these innovations will improve patient outcomes.
🔗 www.ajmc.com/view/experts...
#HealthcareInnovation #Oncology #AI
🔗 www.ajmc.com/view/experts...
#HealthcareInnovation #Oncology #AI
Your breast cancer risk is personal—and understanding it is powerful.
SCRI's Dr. Denise Yardley shares how genetic testing is changing prevention on @newschannel5plus.bsky.social .
🎥 Watch: bit.ly/DrYardleyBCAM
#BCAM #BreastCancerAwareness #EarlyDetection #SCRI
SCRI's Dr. Denise Yardley shares how genetic testing is changing prevention on @newschannel5plus.bsky.social .
🎥 Watch: bit.ly/DrYardleyBCAM
#BCAM #BreastCancerAwareness #EarlyDetection #SCRI
October 9, 2025 at 7:35 PM
Your breast cancer risk is personal—and understanding it is powerful.
SCRI's Dr. Denise Yardley shares how genetic testing is changing prevention on @newschannel5plus.bsky.social .
🎥 Watch: bit.ly/DrYardleyBCAM
#BCAM #BreastCancerAwareness #EarlyDetection #SCRI
SCRI's Dr. Denise Yardley shares how genetic testing is changing prevention on @newschannel5plus.bsky.social .
🎥 Watch: bit.ly/DrYardleyBCAM
#BCAM #BreastCancerAwareness #EarlyDetection #SCRI
We’re celebrating Dr. Howard “Skip” Burris’s remarkable career as he prepares to retire as President & CMO of SCRI.
His legacy: 850+ first-in-human trials, countless lives impacted. 💙
Welcome new leaders and read the full update:
www.scri.com/news/scri-an...
His legacy: 850+ first-in-human trials, countless lives impacted. 💙
Welcome new leaders and read the full update:
www.scri.com/news/scri-an...
October 6, 2025 at 6:08 PM
We’re celebrating Dr. Howard “Skip” Burris’s remarkable career as he prepares to retire as President & CMO of SCRI.
His legacy: 850+ first-in-human trials, countless lives impacted. 💙
Welcome new leaders and read the full update:
www.scri.com/news/scri-an...
His legacy: 850+ first-in-human trials, countless lives impacted. 💙
Welcome new leaders and read the full update:
www.scri.com/news/scri-an...
At 45, Bryan was diagnosed with advanced prostate cancer.
A BRCA mutation led him to a clinical trial through SCRI at Texas Oncology.
Today, his PSA levels are undetectable—and he’s thriving. 💙
#ProstateCancer #BRCA #SCRI #TexasOncology #USOncologyNetwork #ClinicalTrials #CancerResearch
A BRCA mutation led him to a clinical trial through SCRI at Texas Oncology.
Today, his PSA levels are undetectable—and he’s thriving. 💙
#ProstateCancer #BRCA #SCRI #TexasOncology #USOncologyNetwork #ClinicalTrials #CancerResearch
October 2, 2025 at 5:14 PM
At 45, Bryan was diagnosed with advanced prostate cancer.
A BRCA mutation led him to a clinical trial through SCRI at Texas Oncology.
Today, his PSA levels are undetectable—and he’s thriving. 💙
#ProstateCancer #BRCA #SCRI #TexasOncology #USOncologyNetwork #ClinicalTrials #CancerResearch
A BRCA mutation led him to a clinical trial through SCRI at Texas Oncology.
Today, his PSA levels are undetectable—and he’s thriving. 💙
#ProstateCancer #BRCA #SCRI #TexasOncology #USOncologyNetwork #ClinicalTrials #CancerResearch
Bill, 76, joined a clinical trial at SCRI to treat stage IV prostate cancer. His goal: dance at his daughter’s wedding. ✅
Now celebrating a grandchild & still practicing law—while seeing a 15% reduction in disease.
Hope lives here.
🔗 www.scri.com/patients/?co...
#SCRI #ClinicalTrials #ProstateCancer
Now celebrating a grandchild & still practicing law—while seeing a 15% reduction in disease.
Hope lives here.
🔗 www.scri.com/patients/?co...
#SCRI #ClinicalTrials #ProstateCancer
September 29, 2025 at 2:32 PM
Bill, 76, joined a clinical trial at SCRI to treat stage IV prostate cancer. His goal: dance at his daughter’s wedding. ✅
Now celebrating a grandchild & still practicing law—while seeing a 15% reduction in disease.
Hope lives here.
🔗 www.scri.com/patients/?co...
#SCRI #ClinicalTrials #ProstateCancer
Now celebrating a grandchild & still practicing law—while seeing a 15% reduction in disease.
Hope lives here.
🔗 www.scri.com/patients/?co...
#SCRI #ClinicalTrials #ProstateCancer